Raxone (idebenone 150 mg) + Midazolam 2,5 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Drug Interaction
Conditions
Drug-Drug Interaction
Trial Timeline
Sep 1, 2016 → Nov 1, 2016
NCT ID
NCT02887443About Raxone (idebenone 150 mg) + Midazolam 2,5 mg
Raxone (idebenone 150 mg) + Midazolam 2,5 mg is a phase 1 stage product being developed by Santhera Pharmaceuticals for Drug-Drug Interaction. The current trial status is completed. This product is registered under clinical trial identifier NCT02887443. Target conditions include Drug-Drug Interaction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02887443 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-Drug Interaction